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Abstract
Background: Global histone modifications have been implicated in the progression of various tumour entities. Our
study was designed to assess global methylation levels of histone 4 lysine 20 (H4K20me1-3) at different stages of
prostate cancer (PCA) carcinogenesis.
Methods: Global H4K20 methylation levels were evaluated using a tissue microarray in patients with clinically
localized PCA (n = 113), non-malignant prostate disease (n = 27), metastatic hormone-naive PCA (mPCA, n = 30)
and castration-resistant PCA (CRPC, n = 34). Immunohistochemistry was performed to assess global levels of H4K20
methylation levels.
Results: Similar proportions of the normal, PCA, and mPCA prostate tissues showed strong H4K20me3 staining.
CRPC tissue analysis showed the weakest immunostaining levels of H4K20me1 and H4K20me2, compared to other
prostate tissues. H4K20me2 methylation levels indicated significant differences in examined tissues except for
normal prostate versus PCA tissue. H4K20me1 differentiates CRPC from other prostate tissues. H4K20me1 was
significantly correlated with lymph node metastases, and H4K20me2 showed a significant correlation with the
Gleason score. However, H4K20 methylation levels failed to predict PSA recurrence after radical prostatectomy.
Conclusions: H4K20 methylation levels constitute valuable markers for the dynamic process of prostate cancer
carcinogenesis.
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Background
Valuable insight into epigenetics of prostate cancer
(PCA) carcinogenesis offers starting points for potential
new markers of non-invasive cancer diagnosis, progres-
sion and prognosis [1]. Recent observations suggest that
changes in DNA methylation or gene silencing by CpG
island promoter hypermethylation are not isolated
events in inactivation of tumor suppressor genes, but
accompanied by alterations of global histone modifica-
tion levels as common hallmarks of PCA cells [2]. His-
tones are subject to a variety of posttranslational
modifications (e.g. methylation, acetylation) on the N-
terminal tail. These modifications function either by dis-
rupting chromatin contacts or by affecting the recruit-
ment of various proteins to the chromatin and thereby
regulating transcription [3]. Histone lysine methylation
results in transcriptional activation or repression,
depending on the modified lysine site, and can be inten-
sified regarding an increasing number of methylation
marks (mono-, di- and tri- methylation). Histone H4
lysine 20 (H4K20) represents one of the nucleosomal
core histone modifications which is involved in various
cellular processes, depending on its methylation: Mono-
methylated H4K20 (H4K20me1) plays a crucial role in
transcriptional repression and X inactivation [4],
whereas di-methylated H4K20 (H4K20me2) is linked to
cellular mechanisms of DNA reparation based on its
binding ability for 53BP1 at sites of double stranded
DNA damages [5]. Fraga et al. demonstrated an
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(H4K20me3) and cancer, while it is indistinctively clari-
fied whether the reduction of H4K20 is cause or conse-
quence for carcinogenesis [6].
Alterations in histone H4 modifications have been
shown for other cancers [7,8], especially the loss of
lysine 16 acetylation and lysine 20 tri-methylation in
lymphoma, lung, breast and colon cancer cells. The role
of H4K20 methylation has not been investigated suffi-
ciently in genitourinary cancers. While Schneider et al.
have demonstrated that global histone tri-methylation
levels of H4K20 predict cancer-specific survival in blad-
der cancer [9], yet a systemic analysis of H4K20 methy-
lation levels in PCA and its impact on carcinogenesis
remains open. Recent studies suggest that lower levels
of global histone H3 lysine 4 di-methylation - and his-
tone H3 lysine 18 acetylation levels [10] as well as
alterations in the methylation levels of further H3
(H3K4, H3K9) and H4 (H4Ac) histones [11] allow the
prediction of prognosis and biochemical recurrence of
PCA.
Our study investigates global H4K20 mono-, di- and
tri-methylation levels using immunohistochemistry in
various states of prostate carcinogenesis (i.e. clinically
localized PCA, metastatic PCA and castration-resistant
PCA).
Methods
Patients and tissue microarray
A tissue microarray was applied to study the global
H4K20 methylation levels in randomly chosen tissue
from our tissue bank of patients with clinically localized
PCA (patients with PCA undergoing radical prostatect-
omy, n = 113) and non-malignant prostate disease
(patients undergoing radical cystectomy (n = 5) for blad-
der cancer, and transurethral resection of the prostate (n
= 12) or retropubic adenomectomy (n = 6) for benign
prostate enlargement); the tissue microarray was
described earlier [12]. All control samples underwent a
haematoxylin/eosin staining to exclude the presence of
cancer cells and revealed benigne prostate hyperplasia
(n = 17) and normal prostate tissue (n = 6). Surgery has
been performed at the departments of urology at the
Universitätsklinikum Bonn and the Waldkrankenhaus
Bonn between 1995 and 2002. None of the included
patients underwent neoadjuvant hormonal therapy or
radiation prior surgery. The median follow-up period
w a s2 9m o n t h s( r a n g e1 - 1 4 0m o n t h s )w h i c hw a sa v a i l -
able for 77 patients of whom 20 suffered from recur-
rence, defined as a single PSA measurement > 0.2 ng/ml
following radical prostatectomy. See Table 1 for clinical-
pathological parameters. Retrospectively, all cases were
re-evaluated for histopathological staging according the
UICC TNM-staging system published in 2002 and
grading according the Gleason Scoring system published
in 2005. The tissue microarray was prepared from for-
malin-fixed, paraffin-embedded tissue specimens using a
manual device (Beecher Instruments, Sun Prairie, WI,
USA). Three tissue cores (including the lowest and high-
est Gleason grade) were arrayed to obtain a representa-
tive image of the tumour. Further analyses of this study
included a tissue microarray with samples of advanced
PCA undergoing palliative transurethral resection of the
prostate at the departments of urology at the Universi-
tätsklinikum Erlangen and Universitätsklinikum Regens-
burg (also described in [12]), which were derived from
patients with metastatic hormone-naive PCA (mPCA, n
= 30) and castration-resistant PCA (CRPC, n = 34). This
tissue microarray contained a single core of PCA tissue
of each patient. The local ethic committee has approved
this study (ethic vote #289/08).
Immunohistochemistry
The paraffin sections (5 μm )w e r ec u tf r o mt h et i s s u e
microarray block and used within one week with a sub-
sequent deparaffinization, using xylene and applying a
rehydration with graded ethanol. Slides were placed in
target retrieval solution (citrate buffer, pH 6.0) and
heated for 10 minutes at boiling temperature (micro-
wave, 600 W). Following a cooling period of 15 minutes,
Table 1 Clinical-pathological parameters of patients with
prostate cancer and non-malignant prostate disease
PCA
(n = 113)
BPH
(n = 17)
normal
(n = 6)
serum PSA
< 4 ng/ml 9 (7.9%) 0 (0.0%) 0 (0.0%)
4-10 ng/ml 48 (42.5%) 2 (11.7%) 0 (0.0%)
> 10 ng/ml 48 (42.5%) 2 (11.7%) 0 (0.0%)
n.a. 8 (7.1%) 13 (76.5%) 6 (100%)
digital rectal examination
normal 51 (45.1%)
suspicious 50 (44.2%)
n.a. 12 (10.6%)
pathological stage
pT2 61 (54.0%)
pT3a 33 (29.2%)
pT3b 16 (14.1%)
pT4 3 (2.6%)
seminal vesicle infiltration 18 (15.8%)
lymph node metastasis 9 (7.9%)
Gleason Score
< 7 48 (42.5%)
3 + 4 = 7 11 (9.8%)
4 + 3 = 7 11 (9.8%)
8-10 43 (38.0%)
n.a., not available; PCA, prostate cancer; BPH, benign prostate hyperplasia
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treatment with 3% H2O2 for 10 minutes. Afterwards,
the sections were washed with tris-buffered saline and
underwent a 15 minute protein block with normal
swine serum with a subsequent application of the pri-
mary antibodies overnight at 4°C [antibodies were pur-
chased from Upstate, Lake Placid, NY, USA: H4K20me1
(dilution 1:2000; catalogue number 39176; Active
Motife, Carlsbad, CA, USA), H4K20me2 (dilution 1:250;
catalogue number 07-747; Upstate, Lake Placid, NY,
USA), H4K20me3 (dilution 1:400; catalogue number
07-463; Upstate, Lake Placid, NY, USA)]. Immunohisto-
chemical staining was performed using the streptavidine-
biotin-peroxidase complex technique (LSAB+, DAKO
Cytomation, Glostrup, Denmark). The biotin-conjugated
secondary antibody was incubated 30 minutes at room
temperature and the avidin biotin enzyme reagent alike.
The peroxidase was developed with the AEC system
(DAKO). The sections were counterstained with haema-
toxylin and mounted. A semi-quantitative scoring system
has been introduced to evaluate immunostaining results:
The number of positive epithelial cells was estimated per
core and scaled (0, no positive cells; 1, 1-25% positive
cells; 2, 26-50% positive cells; 3, 51-75% positive cells;
and 4, 76-100% positive cells). These scores were multi-
plied with an intensity scale (0, negative; 1, weak; 2, mod-
erate; and 3, intensive staining). The intensity and
frequency score were multiplied and categorized into low
(score: 0-4), moderate (score: 5-8) and high (score: 9-12).
Three cores where evaluated in each patient with clini-
cally localized PCA; a single core was analyzed in patients
with metastatic PCA. The evaluation of immunohisto-
chemical staining has been performed without knowledge
of the clinical-pathological parameters.
Statistical analysis
Ascertained staining scores were applied to the chi-
square test to determine differences of global H4K20
methylation levels in normal prostate tissue and PCA,
or various stages of PCA. A Cox proportional hazard
regression analysis was used to correlate the period of
biochemical recurrence free-survival following radical
prostatectomy with global H4K20 methylation levels or
clinical-pathological parameters. Significance was con-
cluded at p < 0.05. Statistical analyses were performed
using PASW Statistics 18 (SPSS, Chicago, IL, USA).
Results
As expected, we observed a nuclear staining of
H4K20me1-3 (Figure 1) with different levels of H4K20
methylation at various stages of PCA. In general, immu-
nostaining was lowest in H4K20me1, moderate to strong
in H4K20me2 and moderate to high in H4K30me3.
H4K20me1. H4K20me1 staining was significantly lower
in CRPC than in normal prostate tissue, localized PCA or
metastatic PCA (see Figure 2 and Table 2 for details).
The level of H4K20me1 was significantly increased in
patients with lymph node metastases (Figure 3; Table 3).
H4K20me1 was not correlated with PSA recurrence fol-
lowing radical prostatectomy (Table 4).
H4K20me2. H4K20me2 was similar in normal prostate
tissue and localized PCA, whereas its level was signifi-
cantly reduced in tissue of patients with mPCA and
CRPC. The H4K20me2 level was even lower in CRPC
than in mPCA (Table 2, Figure 2). We observed a signif-
icant correlation of Gleason Score and H4K20me2 in
patients with localized PCA (Table 3; Figure 2). Bio-
chemical recurrence following prostatectomy and
H4K20me2 were not correlated (Table 4).
H4K30me3. H4K20me3 levels were similar in normal
prostate tissue, localized PCA, mPCA and CRPC (Table 2),
and we did not observe an association with any clinical-
pathological parameter (Table 3) no PSA recurrence
(Table 4) following radical prostatectomy.
Discussion
The importance of global histone methylation levels has
first been published by Seligson et al. and has not yet
Figure 1 Representative staining of H4K20me1 (A), H4K20me2 (B) and, H4K20me3 (C) in prostate cancer tissue; all antibodies are
showing nuclear staining (magnification ×10; in-box figure magnified ×20).
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cinogenesis and its prognosis [13]. Compared to normal
prostate tissue, the present study displays an aberrant
pattern of H4K20 modifications during PCA progression
with a general hypomethylation of H4K20me1 and
H4K20me2 in mPCA and CRPC.
While H4K20me2 is shown to sufficiently differentiate
between different stages of PCA except for normal pros-
tate tissue versus localized PCA, H4K20me1 sufficiently
differentiates CRPC from other stages of PCA develop-
ment. These findings suggest that modifications in his-
tone methylation may not be applied primarily as
tumour markers, rather than help to distinguish the
Figure 2 The columns show the distribution of the different
global H4K20 methylation levels in non-malignant prostate
tissue (n = 23), localized prostate cancer (PCA; n = 113),
metastatic hormone-naïve prostate cancer (mPCA; n = 30) and
castration-resistant prostate cancer (CRPC; n = 34). H4K20
methylation levels were categorized into weak (≤ 4), moderate (5-8)
and strong (≥ 9).
Table 2 Global H4K20 methylation levels are different at
various stages of prostate cancer
H4K20me1 H4K20me2 H4K20me3
NORMAL vs. PCA p = 0.323 p = 0.261 p = 0.113
NORMAL vs. mPCA p = 0.676 p < 0.001 p = 0.575
NORMAL vs. CRPC p = 0.017 p < 0.001 p = 0.136
PCA vs. mPCA p = 0.483 p < 0.001 p = 0.482
PCA vs. CRPC p = 0.001 p < 0.001 p = 0.345
mPCA vs. CRPC p = 0.030 p = 0.030 p = 0.509
PCA, prostate cancer; mPCA, metastatic prostate cancer; CRPC, castration
resistant prostate cancer
Figure 3 Correlation of global H4K20 methylation levels with
adverse clinical-pathological parameters: H4K20me1 was
positively correlated with lymph node involvement and
H4K20me2 was correlated with Gleason Score.
Table 3 Global H4K20 methylation levels are correlated
to adverse clinical-pathological parameters
H4K20me1 H4K20me2 H4K20me3
preoperative PSA† p = 0.122 p = 0.573 p = 0.151
pT-stage p = 0.122 p = 0.573 p = 0.157
capsular penetration p = 0.094 p = 0.469 p = 0.902
seminal vesicle infiltration p = 0.127 p = 0.947 p = 0.468
lymph node metastases p = 0.002 p = 0.196 p = 0.091
Gleason Score‡ p = 0.191 p = 0.021 p = 0.074
† categorized: PSA < 4 ng/ml, 4-10 ng/ml, > 10 ng/ml; ‡ categorized: Gleason
Sum ≤ 6, 7, ≥ 8
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Analogous findings have been reported by Schneider et
al. [9] regarding the carcinogenesis of bladder cancer,
with decreasing levels of H4K20me1-3 from normal
urothelium over non-musclei n v a s i v eb l a d d e rc a n c e r ,
muscle-invasive bladder cancer to metastatic bladder
cancer. The authors concluded that H4K20me1-3 levels
help identifying patients with poor prognosis after radi-
cal cystectomy
Recent studies indicate H4K20me3 to be strongly
decreased during disease progression of squamous cell
cancer of the lungs and, thus being an important marker
for therapeutic approaches [14]. To date, it remains
unanswered whether hypomethylation is cause or conse-
quence of carcinogenesis, although recent studies suggest
that dynamics in H4K20 methylation contribute to dereg-
ulations in cell cycle control and oncogenic transforma-
tion [15] which is conducive to correlations of H4K20
methylation levels with adverse clinical-pathological
parameters: Interestingly, H4K20me1 was positively cor-
related to lymph node metastases (p = 0.002) which is
consistent with its expression profile in mPCA. Similar
results are demonstrated for H4K20me2, which shows a
positive correlation to the categorized Gleason sum.
Our regression analysis did not allow the prediction of
PSA recurrence after radical prostatectomy via H4K20
methylation levels. In contrast, Zhou et al. reported that
H4K20me3 levels, accompanied by preoperative PSA
levels, allowed risk stratification for PSA recurrence after
radical prostatectomy [16]. It seems that other histone
modifications are more important prognostic markers in
patients with PCA: H3K4me1 [12] and H3K4me2 [10]
were significant predictors of PSA recurrence following
radical prostatectomy. In comparison, H3K27 methyla-
tion is correlated with many adverse clinical-pathological
parameters (i.e. Gleason Score, pathological stage) but
not with PSA recurrence [17]. It has to be noted that fol-
low-up information was only available for 77 patients in
our study, and also established predictive parameters like
pathological stage/grade failed to correlate with PCA
recurrence indicating insufficient statistical power.
Furthermore, Ellinger et al. were able to show the actey-
lated Histone H3 (H3Ac) and di-methylated H3 lysine 9
(H3K9me2) to be valuable discriminators between non-
malignant prostate tissue and PCA with a high sensitivity
(> 78%) and specificity (> 91%) [12]. Although recent stu-
dies suggest the PSA value and the PSADT to be asso-
ciated with a risk development of metastatic disease in
CRPC patients [18] there is no clear surrogate so far
which can determine disease progression or progression
after first-line chemotherapy in these patients.
Though, H4K20me3 does not allow significant differ-
entiations between various stages of PCA it shows
strong methylation levels in mPCA and CRPC, com-
pared to H4K20me1/2 (see Figure 3). These observa-
tions might accompany recent findings by Vertino et al.
[19], who describe the tri-methylation of H4K20 via
SUV420H2 to play a crucial role in silencing tumor sup-
pressor genes, such as TMS1 (target of methylation-
induced silencing), which encodes for caspase recruit-
ment domains, contributing to the promotion of apop-
tosis in PCA cells [20] and has been reported to be
prognostic for PCA carcinogenesis [21]. Although this
study does not address effects of H4K20 methylation
changes on gene expression, it offers perspectives for
further investigations on which mechanisms contribute
to hypomethylated states in different stages of carcino-
genesis. To date there are no demethylases detected [22]
which are accountable for the significant reduction of
H4K20me1/2 methylated states in mPCA and CRPC.
The expression level of H4K20 methylases is yet no
explored in PCA; however, loss of the H4K20 methylase
Suv4-20h2 were associated with lower levels of
H4K20me3 in a rodent-model of hepatocarcinogenesis
[7] and breast cancer cell lines [8].
Conclusions
H4K20 methylation levels constitute valuable markers for
the dynamic process of prostate cancer carcinogenesis.
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